Skip to main content Accessibility help
×
Home
  • Print publication year: 2008
  • Online publication date: December 2009

13 - Viral Hepatitis

from Part I - Systems
    • By Ramin Jamshidi, Adjunct Professor of Physics University of San Francisco, University of California, San Francisco School of Medicine, San Francisco, CA, Francis Yao, Professor of Clinical Medicine and Surgery, Associate Medical Director, Liver Transplantation University of California, San Francisco School of Medicine, San Francisco, CA
  • Edited by Rachel L. Chin, University of California, San Francisco
  • Publisher: Cambridge University Press
  • DOI: https://doi.org/10.1017/CBO9780511547454.014
  • pp 59-64

Summary

INTRODUCTION

A number of viruses have been found to primarily infect hepatocytes, though not all cause clinically relevant disease. The classically recognized hepatotropic viruses are the hepatitis A, B, C, D, E, and G viruses. Of clinically apparent acute and chronic hepatitis, 10% to 20% is cryptogenic in nature and is thought to be caused by as yet unidentified viruses.

EPIDEMIOLOGY

Hepatitis viruses A and E are transmitted via the fecal-oral route, whereas B, C, and D are spread primarily via contact with infected blood or other body fluid. Hepatitis G is transferred by either route, but is not proven to cause clinical disease. Fecal-oral transmission of the A and E viruses is responsible for most acute outbreaks, whereas B and C constitute a major chronic public health burden.

Hepatitis A virus (HAV) infection accounts for approximately 25,000 cases of acute hepatitis annually in the United States, with as many as 40% of the urban population having serologic evidence of past infection. Outbreaks often affect clusters of persons exposed to a single source, such as a food handler or contaminated central water supply.

Persons infected with hepatitis B virus (HBV) carry the virus in all bodily fluids (blood, breast milk, saliva, semen, and urine). HBV can cause both acute and chronic hepatitis, the latter conferring risk of cirrhosis and hepatocellular carcinoma. It is estimated that 200 million people worldwide are chronically infected with HBV.

Related content

Powered by UNSILO
REFERENCES
Dienstag, J L, McHutchison, J G. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology 2006;130(1):231–64.
Fox R K, Wright T L. Viral hepatitis. In: Friedman, S, ed. Current diagnosis & treatment in gastroenterology, 2nd ed. New York: McGraw-Hill, 2003.
Ganem, D, Prince, A. Hepatitis B virus infection – natural history and clinical consequences. N Engl J Med 2004;350(11):1118–29.
Menon, K V N. Non-a to e hepatitis. Curr Opin Infect Dis 2002;15:529–34.
Navarro, V J, Senior, J R. Drug-related hepatotoxicity. N Engl J Med 2006;354(7):731–9.
Pawlotsky, J M. Molecular diagnosis of viral hepatitis. Gastroenterology 2002;122(6):1554–68.
Roberts, S E, Goldacre, M J, Yeates, D. Trends in mortality after hospital admission for liver cirrhosis in an English population. Gut 2005;54(11):1615–21.
Sookian, S. Liver disease during pregnancy: acute viral hepatitis. Ann Hepatol 2006;5(3):231–6.
ADDITIONAL READINGS
Davern T J. Fulminant hepatic failure. In: Bayless, T M, Diehl, A M eds. Advanced therapy in gastroenterology and liver disease, 5th ed. Ontario: BC Decker, 2006:629–37.
Pratt, D S, Kaplan, M M. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med 2000;342(17): 1266–71.